Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

(2020) Meletios Dimopoulos et al.   LANCET

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

(2019) Maria-Victoria Mateos et al.   Clinical Lymphoma Myeloma & Leukemia

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

(2019) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

(2019) Thomas G. Martin et al.   Cells

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

(2019) Philippe Moreau et al.   Future Oncology

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

(2017) Juan-Jose Lahuerta et al.   JOURNAL OF CLINICAL ONCOLOGY

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

(2017) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Living with the burden of relapse in multiple myeloma from the patient and physician perspective

(2017) Cyrille Hulin et al.   LEUKEMIA RESEARCH

Second primary malignancies in multiple myeloma: an overview and IMWG consensus

(2016) P. Musto et al.   ANNALS OF ONCOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

(2016) Shaji Kumar et al.   LANCET ONCOLOGY

Multiple myeloma epidemiology and survival: A unique malignancy

(2016) Dickran Kazandjian   SEMINARS IN ONCOLOGY

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study

(2014) Vishal Bhatnagar et al.   CANCER

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study

(2012) M. F. Janssen et al.   QUALITY OF LIFE RESEARCH

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

(2011) M. Herdman et al.   QUALITY OF LIFE RESEARCH